Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.

Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL.

Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):934-41. doi: 10.1002/pds.1992.

PMID:
20623519
2.

Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.

Harpin VA.

Arch Dis Child Educ Pract Ed. 2008 Apr;93(2):58-65. doi: 10.1136/adc.2006.106864. Review.

PMID:
18356307
3.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
4.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
5.

Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.

Kaplan G, Newcorn JH.

Pediatr Clin North Am. 2011 Feb;58(1):99-120, xi. doi: 10.1016/j.pcl.2010.10.009. Review.

PMID:
21281851
6.
7.

Pharmacological management of attention-deficit hyperactivity disorder.

Reeves G, Schweitzer J.

Expert Opin Pharmacother. 2004 Jun;5(6):1313-20. Review.

PMID:
15163276
8.

Attention deficit hyperactivity disorder in adults.

Rösler M, Casas M, Konofal E, Buitelaar J.

World J Biol Psychiatry. 2010 Aug;11(5):684-98. doi: 10.3109/15622975.2010.483249. Review.

PMID:
20521876
9.

Medications for adolescents with attention-deficit/hyperactivity disorder.

Soileau EJ Jr.

Adolesc Med State Art Rev. 2008 Aug;19(2):254-67, viii-ix. Review.

PMID:
18822831
10.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
11.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
12.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
13.

[My child is so restless].

Schlamp D.

MMW Fortschr Med. 2007 Mar 8;149(10):39-40. Review. German.

PMID:
17408047
14.

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.

Bushe CJ, Savill NC.

J Psychopharmacol. 2014 Mar;28(3):204-11. doi: 10.1177/0269881113478475. Epub 2013 Feb 25. Review.

PMID:
23438503
15.

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].

Ludolph AG, Kölch M, Plener PL, Schulze UM, Spröber N, Fegert JM.

Z Kinder Jugendpsychiatr Psychother. 2009 Sep;37(5):405-11. doi: 10.1024/1422-4917.37.5.405. Review. German.

PMID:
19739058
16.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
17.

A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. Epub 2013 Apr 6. Review.

19.

Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.

Fredriksen M, Halmøy A, Faraone SV, Haavik J.

Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. Review.

PMID:
22917983
20.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk